NCT06582966View on ClinicalTrials.gov

Weekly Doxycycline DOT for STI Prevention Among Cisgender Women Taking HIV PrEP in Kisumu, Kenya

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 13, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
STI
Interventions
DRUG

Doxycyclin

Open label, single-arm, pilot study of 60 cisgender women taking HIV PrEP in Kisumu, Kenya will be given doxycycline 200 mg orally once weekly with clinical follow-up including quarterly STI testing and treatment for six months.

Trial Locations (1)

Unknown

Kenya Medical Research Institute -KEMRI, Kisumu

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of Washington

OTHER

NCT06582966 - Weekly Doxycycline DOT for STI Prevention Among Cisgender Women Taking HIV PrEP in Kisumu, Kenya | Biotech Hunter | Biotech Hunter